Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;6(1):15-31.
doi: 10.1177/1756283X12453636.

Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?

Affiliations

Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?

Hilda Wong et al. Therap Adv Gastroenterol. 2013 Jan.

Abstract

It is increasingly recognized that gastric cancer is a heterogeneous disease which may be divided into subgroups based on histological, anatomical, epidemiological and molecular classifications. Distinct molecular drivers and tumor biology, and thus different treatment targets and predictive biomarkers, may be implicated in each subtype. However, there is little evidence in the literature regarding the correlation among these different classifications, and particularly the molecular aberrations present in each subtype. In this review, we approach advanced gastric cancer (AGC) by presenting aberrant molecular pathways and their potential therapeutic targets in gastric cancer according to histological and anatomical classification, dividing gastric cancer into proximal nondiffuse, distal nondiffuse and diffuse disease. Several pathways are involved predominantly, although not exclusively, in different subtypes. This may help to explain the disappointing results of many published AGC trials in which study populations were heterogeneous regardless of clinicopathological characteristics of the primary tumor. Histological and anatomical classification may provide insights into tumor biology and facilitate selection of an enriched patient population for targeted agents in future studies and in the clinic. However, some molecular pathways implicated in gastric cancer have not been studied in correlation with histological or anatomical subtypes. Further studies are necessary to confirm the suggestion that such classification may predict tumor biology and facilitate selection of an enriched patient population for targeted agents in future studies and in the clinic.

Keywords: Advanced gastric cancer; angiogenic pathway; biomarker; epidermal growth factor pathway; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

Figures

Figure 1.
Figure 1.
Subtypes of gastric cancer based on anatomical and histological classification, and important molecular targets implicated in each subtype. EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; GEJ, gastroesophageal junction; HER, human epidermal growth factor receptor; MMP, matrix metalloproteinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3 kinase; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor. (Illustration courtesy of Alessandro Baliani, Copyright © 2012.)
Figure 2.
Figure 2.
Schematic diagram of signaling pathways in gastric cancer and targets for molecular therapy. EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; FGFR, fibroblast growth factor receptor; HER, human epidermal growth factor receptor; MMP, matrix metalloproteinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3 kinase; PTEN, phosphatase and tensin homolog; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor. (Illustration courtesy of Alessandro Baliani, Copyright © 2012.)

Similar articles

Cited by

References

    1. Al-Kasspooles M., Moore J., Orringer M., Beer D. (1993) Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 54: 213–219 - PubMed
    1. Alsina M., Ko A., Garcia De Paredes M., Rivera F., Schwartzberg L., Fattaey A., et al. (2011) Clinical and pharmacodynamic (PD) results of TEL0805 trial: a phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer. J Clin Oncol 29(Suppl.): abstract 4122
    1. An J., Kim K., Choi M., Noh J., Sohn T., Bae J., et al. (2010) Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int J Cancer 126: 2904–2913 - PubMed
    1. Asaka M., Kimura T., Kato M., Kudo M., Miki K., Ogoshi K., et al. (1994) Possible role of Helicobacter pylori infection in early gastric cancer development. Cancer 73: 2691–2694 - PubMed
    1. Bang Y., Chung H., Xu J., Lordick F., Sawaki A., Lipatov O., et al. (2009) Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 27(15 Suppl.): abstract 4556

LinkOut - more resources